Compare DFDV & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DFDV | GNLX |
|---|---|---|
| Founded | 2018 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.4M | 110.4M |
| IPO Year | 2022 | 2022 |
| Metric | DFDV | GNLX |
|---|---|---|
| Price | $5.44 | $2.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $45.00 | $17.25 |
| AVG Volume (30 Days) | ★ 1.7M | 307.9K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,099,660.00 | $8,000.00 |
| Revenue This Year | $32.58 | N/A |
| Revenue Next Year | $23.65 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 4.82 | N/A |
| 52 Week Low | $2.44 | $2.29 |
| 52 Week High | $18.97 | $8.54 |
| Indicator | DFDV | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 69.94 | 42.93 |
| Support Level | $2.78 | $2.51 |
| Resistance Level | $5.90 | $2.95 |
| Average True Range (ATR) | 0.50 | 0.15 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 75.80 | 28.57 |
DeFi Development Corp is a U.S. company committed to building its treasury around Solana (SOL), a fast-growing blockchain infrastructure platform. This equity delivers shareholders tangible exposure to SOL price movement and staking rewards, making the firm a proxy for the Solana ecosystem. The treasury extends to running its own validator infrastructure, allowing DFDV to actively participate in and benefit from the Solana network expansion. The firm has two segments: Digital Asset Treasury ("Treasury") and Real Estate Platform ("Real Estate"). The company generates the majority of its revenue from the Treasury segment.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.